Analysis of indications and treatment areas of ceritinib capsules

Ceritinib is an oral ALK inhibitor that has been approved by many countries around the world. It is mainly suitable for the treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC), especially for patients who have experienced resistance or intolerance to crizotinib (Crizotinib). It provides a more powerful treatment option. Non-small cell lung cancer accounts for the majority of lung cancer patients worldwide, and ALK gene rearrangement only occurs in a small number of patients. Ceritinib is a targeted drug tailored for this type of "gene-driven" lung cancer. With the popularization of molecular testing in lung cancer treatment strategies, although the proportion of ALK-positive patients is small, due to their strong response to targeted therapy and the efficacy far exceeding that of traditional chemotherapy, it has gradually become one of the key areas of precision medicine.

In clinical use, ceritinib not only demonstrates powerfulALK inhibitory ability, but also shows better penetration into brain metastases, making its role in the central nervous system metastasis of lung cancer attracting much attention. Its mechanism of action is mainly to inhibit the proliferation and spread of tumor cells by blocking the abnormally activated ALK tyrosine kinase signaling pathway in cancer cells. Unlike traditional treatments that rely on systemic toxicity caused by radiotherapy or chemotherapy, ceritinib can more specifically "cut off" the key driving pathways that cancer cells rely on to survive, significantly improving patients' quality of life and survival.

In terms of indications, ceritinib is currently recommended as a first- or second-line treatment for patients with ALK-positive NSCLC, especially after failure of crizotinib treatment. Due to more sophisticated drug design, ceritinib can overcome some of the resistance mutations produced by crizotinib and regain its inhibitory effect. Therefore, when formulating treatment strategies, doctors usually determine whether ceritinib is suitable for use based on genetic testing results and the patient's past treatment response.

Reference materials:https://go.drugbank.com/drugs/DB09063